This clinical trial is focused on individuals who have experienced a stroke at a young age, specifically between 18 and 49 years old, without a known cause. The study is investigating the effects of stopping or continuing the use of blood thinners, also known as antiplatelet therapy, which are medications that help prevent blood clots. The medications being studied include Plavix (containing the active substance clopidogrel), Clopidogrel Viatris (also containing clopidogrel), acetylsalicylic acid (commonly known as aspirin), and a combination of dipyridamole and acetylsalicylic acid.

The purpose of the study is to determine whether stopping these blood thinners is as safe and effective as continuing them in preventing major cardiovascular events, such as another stroke or heart attack, three to ten years after the initial stroke. Participants in the study will be randomly assigned to either continue or stop their antiplatelet therapy. Some participants may receive a placebo, which looks like the medication but does not contain any active ingredients. The study will monitor participants over a period of time to observe any major health events, including strokes, heart attacks, or other serious conditions.

Throughout the study, researchers will also assess other factors such as the risk of major bleeding, overall survival, cost-effectiveness, and quality of life. The study aims to provide valuable information on the long-term management of young stroke patients and help guide future treatment decisions. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.